TScan Therapeutics Shares Outstanding History (TCRX)
TScan Therapeutics reported 56.9M shares outstanding at the end of fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 56.9M | 310,996 | +0.55% |
| 2024 | 2024-12-31 | 56.6M | 8.8M | +18.32% |
| 2023 | 2023-12-31 | 47.8M | 23.6M | +97.43% |
| 2022 | 2022-12-31 | 24.2M | 249,012 | +1.04% |
| 2021 | 2021-12-31 | 24.0M | 22.8M | +2010.91% |
| 2020 | 2020-12-31 | 1.1M | — | — |
TScan Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 67.8M | 11.0M | +19.44% |
| Q1 2026 | 2026-03-31 | 60.1M | 3.5M | +6.20% |
| Q4 2025 | 2025-12-31 | 56.9M | — | — |
| Q3 2025 | 2025-09-30 | 56.7M | — | — |
| Q2 2025 | 2025-06-30 | 56.7M | — | — |
| Q1 2025 | 2025-03-31 | 56.6M | — | — |
| Q4 2021 | 2021-12-31 | 24.0M | 22.8M | +2010.91% |
| Q2 2021 | 2021-06-30 | 1.4M | — | — |
| Q4 2020 | 2020-12-31 | 1.1M | — | — |
TScan Therapeutics shares outstanding trends
Over the last five fiscal years, TScan Therapeutics's shares outstanding moved from 1.1M to 56.9M, a change of 55.8M. The latest reported quarter, Q2 2026, shows 67.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗